Yasser Khaled, MD
Medical Oncology · Orlando, FLNPI 1023194982
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $362,550 of the $444,281 with a category attached, or 81.6%. 22 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 25.4% of the total. Reporting peaked in 2023 at $131,706 and has fallen 62.3% since, to $49,629 in 2025. Among medical oncology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 321 payments — averaging $1384.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$113K
- E.r. Squibb & Sons, L.L.C.$85K
- Gilead$81K
- Takeda Pharmaceuticals U.S.A., Inc.$32K
- Seagen Inc.$27K
- Amgen$24K
- plus $82K from 16 others
Across 7 payments — averaging $7571.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$31K
- E.r. Squibb & Sons, L.L.C.$11K
- Bristol Myers Squibb$10K
- National Marrow Donor Program$1K
What the payments were for
- Consulting fees$42,97610%
- Speaking & faculty fees$362,55082%
- Travel & lodging$27,4306%
- Food & beverage$11,1313%
- Education$1950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 74 | $113,015 |
| E.r. Squibb & Sons, L.L.C. | 37 | $85,028 |
| Gilead | 57 | $81,465 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $31,862 |
| Seagen Inc. | 18 | $27,243 |
| Amgen | 17 | $24,148 |
| Rigel Pharmaceuticals, Inc. | 15 | $22,459 |
| GSK | 11 | $20,592 |
| Adaptive Biotechnologies Corporation | 9 | $17,887 |
| Bristol Myers Squibb | 21 | $13,479 |
| Sanofi | 6 | $4,095 |
| Novartis | 13 | $848 |
| Astellas Pharma US Inc | 6 | $447 |
| Johnson & Johnson | 3 | $419 |
| Incyte Corporation | 4 | $377 |
| Legend Biotech USA Inc. | 4 | $265 |
| Sanofi-aventis U.S. LLC | 4 | $206 |
| Janssen Scientific Affairs, LLC | 2 | $159 |
| Servier Pharmaceuticals LLC | 1 | $122 |
| La Jolla Pharmaceutical Company | 1 | $112 |
| Autolus Inc | 2 | $31 |
| Pfizer | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$444,281 in reported general payments places this provider in the 95th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 18 | $300,707 |
| CresembaIsavuconazonium Sulfate | 41 | $245,448 |
| IclusigPonatinib Hcl | 11 | $225,278 |
| PrevymisLetermovir | 14 | $98,980 |
| Posaconazole | 14 | $33,339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $377 | $300,70718 claims |
| Astellas Pharma US IncCresemba | $447 | $245,44841 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Iclusig | $31,862 | $225,27811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Orlando
- Raji ShameemOrlando$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Rebecca MorooseOrlando$543K
- Guru SonpavdeOrlando$400K
- Rushang PatelOrlando$399K
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Mohammad JahanzebBoca Raton$1.3M
- Reshma MahtaniPlantation$608K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.